.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Julphar
Moodys
UBS
Merck
Queensland Health
Teva
Citi
Fish and Richardson
Chubb

Generated: December 16, 2017

DrugPatentWatch Database Preview

AVINZA Drug Profile

« Back to Dashboard

Which patents cover Avinza, and when can generic versions of Avinza launch?

Avinza is a drug marketed by King Pharms Llc and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has fourteen patent family members in twelve countries.

The generic ingredient in AVINZA is morphine sulfate. There are twenty-three drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Drug patent expirations by year for AVINZA

Pharmacology for AVINZA

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

Medical Subject Heading (MeSH) Categories for AVINZA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-001Mar 20, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-006Dec 18, 2008DISCNNoNo► Subscribe► SubscribeY► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-005Dec 18, 2008DISCNNoNo► Subscribe► SubscribeY► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-002Mar 20, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-004Mar 20, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-003Mar 20, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: AVINZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-001Mar 20, 2002► Subscribe► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-004Mar 20, 2002► Subscribe► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-006Dec 18, 2008► Subscribe► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-003Mar 20, 2002► Subscribe► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-002Mar 20, 2002► Subscribe► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-005Dec 18, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for AVINZA

Drugname Dosage Strength RLD Submissiondate
morphine sulfateExtended-release Capsules45 mg and 75 mgAvinza7/30/2009
morphine sulfateExtended-release Capsules30 mg, 60 mg, 90 mg and 120 mgAvinza6/4/2007

International Patent Family for Tradename: AVINZA

Country Document Number Estimated Expiration
Germany69721845► Subscribe
Denmark1023051► Subscribe
Canada2558783► Subscribe
European Patent Office1023051► Subscribe
Japan4535613► Subscribe
Japan2001520187► Subscribe
World Intellectual Property Organization (WIPO)9920255► Subscribe
Taiwan520298► Subscribe
Austria239454► Subscribe
Portugal1023051► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Fish and Richardson
Julphar
Daiichi Sankyo
Fuji
Farmers Insurance
Queensland Health
Covington
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot